What is claimed is:

1. A multivalent immunogenic composition, comprising: 13 distinct polysaccharide-protein conjugates, together with a physiologically acceptable vehicle, wherein each of the conjugates comprises a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae* conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

2. The immunogenic composition of claim 1, wherein the carrier protein is CRM₁₉₇.

3. The immunogenic composition of claim 1, further comprising an adjuvant.

4. The immunogenic composition claim 3, wherein the adjuvant is an aluminum-based adjuvant.

5. The immunogenic composition of claim 4, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.

6. The immunogenic composition of claim 5, wherein the adjuvant is aluminum phosphate.

7. A method of inducing an immune response to a *Streptococcus pneumoniae* capsular polysaccharide conjugate, comprising administering to a human an immunologically effective amount of the immunogenic composition of claim 1.

8. The method of claim 7, wherein the immunogenic composition administered is a single 0.5 mL dose formulated to contain: 2 µg of each saccharide, except for 6B at 4 µg; approximately 29 µg CRM₁₉₇ carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients.
9. A multivalent immunogenic composition, comprising polysaccharide-protein conjugates together with a physiologically acceptable vehicle, wherein each of the conjugates comprises a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae* conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotype 3 and at least one additional serotype.

10. The immunogenic composition of claim 9, wherein the additional serotype is selected from the group consisting of serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

11. The immunogenic composition of claim 9, wherein the carrier protein is CRM\(_{197}\).

12. The immunogenic composition of claim 9, further comprising an adjuvant.

13. The immunogenic composition claim 12, wherein the adjuvant is an aluminum-based adjuvant.

14. The immunogenic composition of claim 13, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.

15. The immunogenic composition of claim 14, wherein the adjuvant is aluminum phosphate.

16. A method of inducing an immune response to a *Streptococcus pneumoniae* capsular polysaccharide conjugate, comprising administering to a human an immunologically effective amount of the immunogenic composition of claim 9.

17. The method of claim 16, wherein the immunogenic composition administered is a single 0.5 mL dose formulated to contain: 2 μg of each saccharide,
except for 6B at 4 µg; approximately 25 µg CRM197 carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients.

18. A multivalent immunogenic composition, comprising polysaccharide-protein conjugates together with a physiologically acceptable vehicle, wherein each of the conjugates comprises a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae* conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and at least one additional serotype.

19. The immunogenic composition of claim 18, wherein said additional serotype is selected from the group consisting of serotypes 1, 3, 5, 6A, 7F, and 19A.

20. The immunogenic composition of claim 18, wherein the carrier protein is CRM197.

21. The immunogenic composition of claim 18, further comprising an adjuvant.

22. The immunogenic composition claim 21, wherein the adjuvant is an aluminum-based adjuvant.

23. The immunogenic composition of claim 22, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.

24. The immunogenic composition of claim 23, wherein the adjuvant is aluminum phosphate.

25. A method of inducing an immune response to a *Streptococcus pneumoniae* capsular polysaccharide conjugate, comprising administering to a human an immunologically effective amount of the immunogenic composition of claim 18.
26. The method of claim 25, wherein the immunogenic composition administered is a single 0.5 mL dose formulated to contain: 2 µg of each saccharide, except for 6B at 4 µg; approximately 29 µg CRM197 carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients.

27. The invention substantially such as herein described.

Dated this 31st day of March 2006.

Mrs. L. balasubrahmanyam
Applicant’s Agent